Balance Sheet Components

Selected balance sheet components consist of the following:



(In millions)	March 31, 2014		December 31, 2013
Inventories:
Raw materials	$	550.4	$	484.6
Work in process	321.4		310.1
Finished goods	866.1		870.0
	$	1,737.9	$	1,664.7



Property, plant and equipment:
Land and improvements	$	84.5	$	72.7
Buildings and improvements	803.9		747.0
Machinery and equipment	1,691.4		1,698.4
Construction in progress	235.2		207.7
	2,815.0		2,725.8
Less accumulated depreciation	1,110.0		1,062.7
	$	1,705.0	$	1,663.1



Other current liabilities:
Legal and professional accruals, including litigation accruals	$	146.2	$	146.1
Payroll and employee benefit plan accruals	199.4		289.0
Accrued sales allowances	308.3		281.1
Accrued interest	69.3		68.5
Fair value of financial instruments	9.2		74.3
Other	516.9		530.4
	$	1,249.3	$	1,389.4

The value of contingent consideration included in other current liabilities is $250 million at March 31, 2014 and December 31, 2013. Contingent consideration included in other long-term obligations is $423.1 million and $414.6 million at March 31, 2014 and December 31, 2013, respectively. Included in prepaid expenses and other current assets is $131.5 million and $129.5 million of restricted cash at March 31, 2014 and December 31, 2013, respectively. An additional $100 million of restricted cash is classified as a component of other long-term assets at March 31, 2014 and December 31, 2013, principally related to amounts deposited in escrow, or restricted amounts, for potential contingent consideration payments related to the Agila acquisition.

The Company’s equity method investments in clean energy partnerships, whose activities qualify for income tax credits under section 45 of the U.S. Internal Revenue Code, totaled $390.7 million and $401.7 million at March 31, 2014 and December 31, 2013, respectively, and are included in other assets in the Condensed Consolidated Balance Sheets. Liabilities related to these investments totaled $413.6 million and $415.4 million at March 31, 2014 and December 31, 2013, respectively. At March 31, 2014, $370.8 million of these liabilities are included in other long-term obligations and $42.8 million are included in other current liabilities in the Condensed Consolidated Balance Sheets.

As part of the Agila acquisition, the Company acquired a 50% interest in Sagent Agila, which was established in 2007 between Agila and Sagent Pharmaceuticals, Inc. and is accounted for using the equity method of accounting. Sagent Agila was established to allow for the development, manufacturing and distribution of certain generic injectable products in the U.S. market. The initial term of the venture expires upon the tenth anniversary of the formation. The equity method investment included in other assets totaled $119.3 million and $123.2 million at March 31, 2014 and December 31, 2013, respectively, in the Condensed Consolidated Balance Sheets. The results of Sagent Agila were not material to Mylan’s Condensed Consolidated Financial Statements.